Charles River Laboratories International (NYSE:CRL) Price Target Raised to $175.00

Charles River Laboratories International (NYSE:CRL) had its target price boosted by UBS Group from $170.00 to $175.00 in a report released on Wednesday,Benzinga reports. The firm currently has a neutral rating on the medical research company’s stock.

Several other brokerages have also recently issued reports on CRL. Bank of America raised Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price objective for the company in a report on Monday, December 15th. Robert W. Baird set a $193.00 price objective on shares of Charles River Laboratories International in a research report on Thursday, February 19th. Wall Street Zen downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. Evercore lifted their target price on shares of Charles River Laboratories International from $250.00 to $260.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Finally, Morgan Stanley set a $185.00 price target on shares of Charles River Laboratories International in a research report on Monday, December 1st. Ten investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $203.57.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $178.67 on Wednesday. The firm’s fifty day simple moving average is $197.80 and its 200-day simple moving average is $179.93. The company has a quick ratio of 1.02, a current ratio of 1.29 and a debt-to-equity ratio of 0.67. The stock has a market cap of $8.80 billion, a PE ratio of -60.36, a price-to-earnings-growth ratio of 3.00 and a beta of 1.63. Charles River Laboratories International has a fifty-two week low of $91.86 and a fifty-two week high of $228.88.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, February 18th. The medical research company reported $2.39 EPS for the quarter, topping analysts’ consensus estimates of $2.33 by $0.06. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The firm had revenue of $994.23 million for the quarter, compared to the consensus estimate of $986.98 million. During the same quarter in the previous year, the firm earned $2.66 earnings per share. The firm’s revenue was down .8% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. Analysts expect that Charles River Laboratories International will post 9.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Charles River Laboratories International

Several hedge funds have recently made changes to their positions in the business. Invesco Ltd. lifted its position in Charles River Laboratories International by 115.8% during the fourth quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock worth $537,828,000 after buying an additional 1,446,972 shares during the period. Massachusetts Financial Services Co. MA purchased a new position in shares of Charles River Laboratories International during the 4th quarter worth about $176,478,000. Victory Capital Management Inc. boosted its position in shares of Charles River Laboratories International by 9,938.8% in the fourth quarter. Victory Capital Management Inc. now owns 691,474 shares of the medical research company’s stock worth $137,935,000 after acquiring an additional 684,586 shares during the last quarter. Ameriprise Financial Inc. grew its holdings in Charles River Laboratories International by 1,491.1% in the third quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company’s stock valued at $96,005,000 after purchasing an additional 575,039 shares during the period. Finally, National Bank of Canada FI grew its holdings in Charles River Laboratories International by 117.7% in the third quarter. National Bank of Canada FI now owns 946,769 shares of the medical research company’s stock valued at $148,131,000 after purchasing an additional 511,901 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.